|Bid||301.50 x 800|
|Ask||301.70 x 1100|
|Day's range||299.35 - 304.92|
|52-week range||195.50 - 314.00|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||44.98|
|Earnings date||04 Aug 2022|
|Forward dividend & yield||3.92 (1.31%)|
|Ex-dividend date||13 May 2022|
|1y target est||304.28|
Eli Lilly and Company (NYSE: LLY) will host a webcast on Tuesday, June 7, 2022 to discuss the company's diabetes and obesity portfolio and its presentations at the American Diabetes Association's 82nd Scientific Sessions. The webcast will begin at 11:30 a.m. Eastern time and remarks will focus on results from the tirzepatide SURMOUNT-1 clinical trial, as well as Lilly's once-weekly basal insulin and early-phase incretins.
The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.